In order to deliver a personalised, responsive service and to improve the site, we remember and store information about how you use it. This is done using simple text files called cookies which sit on your computer. By continuing to use this site and access its features, you are consenting to our use of cookies. To find out more about the way drugeruptiondata.com uses cookies please read our 'Cookie Policy'.
- TRADE NAME: Rozlytrek (Genentech)
- INDICATIONS:
Treatment of adult patients with metastatic non-small cell lung cancer whose tumors are ROS1-positive.
Treatment of adult and pediatric patients 12 years of age and older with solid tumors that have a neurotrophic tyrosine receptor kinase gene fusion without a known acquired resistance mutation.
Treatment of solid tumors that are metastatic or have progressed following treatment or have no satisfactory alternative therapy.
- CLASS: Anaplastic lymphoma kinase (ALK) inhibitor, Kinase inhibitor, Tropomyosin receptor kinase inhibitor
- HALF-LIFE: 20 hours; 40 hours (major metabolite)
- FDA APPROVAL DATE: 08/15/2019
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Moderate and Strong CYP3A Inducers, Moderate and strong CYP3A inhibitors - PREGNANCY: Can cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and use of effective contraception. Advise not to breastfeed.
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 11/26/2024
